Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

112.55 +2.28 (+2.07%)

Streaming Delayed Price Updated: 2:36 PM EST, Feb 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients ↗

October 16, 2025

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile.

Via Benzinga

Merck & Co. Inc. (NYSE:MRK) Demonstrates Dividend Strength and Sustainability ↗

October 16, 2025

Discover Merck (MRK), a top dividend stock with a sustainable 3.70% yield, strong profitability, and a solid financial health rating for reliable long-term income.

Via Chartmill

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer

October 16, 2025

From Merck & Co., Inc.

Via Business Wire

Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds

October 15, 2025

New York, NY – October 15, 2025 – The Dow Jones Industrial Average (DJIA) experienced a fractional dip today, reflecting a palpable sense of caution pervading market sentiment. While other major...

Via MarketMinute

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials ↗

October 15, 2025

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes.

Via Benzinga

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗

October 14, 2025

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion.

Via Benzinga

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

October 15, 2025

From Merck & Co., Inc.

Via Business Wire

Can $10,000 in Merck Stock Turn Into $50,000 by 2030? ↗

October 14, 2025

The pharmaceutical giant has seen brighter days.

Via The Motley Fool

Topics Intellectual Property

Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?

October 13, 2025

Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to...

Via MarketMinute

Topics Artificial Intelligence

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm

October 13, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk ↗

October 13, 2025

Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype?

Via MarketBeat

Topics Artificial Intelligence

Dow Jones Soars on Trump's Tariff Remarks, Signaling Market Volatility Amidst Trade Policy Shifts

October 13, 2025

New York, NY – October 13, 2025 – The Dow Jones Industrial Average has experienced significant upward momentum in recent months, notably jumping by hundreds of points on multiple occasions in early...

Via MarketMinute

Topics Economy Government Stocks

Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday ↗

October 13, 2025

Via Benzinga

Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? ↗

October 13, 2025

Now may be the time to invest in drug companies, as they just slipped the tariff noose.

Via The Motley Fool

Topics ETFs Government World Trade

Global Markets Diverge: Asian Shares Stumble Amid US-China Trade Tensions, While Wall Street Futures Rebound

October 12, 2025

Global financial markets are currently experiencing a significant divergence, with Asian shares facing considerable pressure due to escalating US-China trade tensions, while Wall Street futures have...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Inflation's Shadow Lengthens: September CPI Ignites Fed Caution Amidst Government Shutdown

October 10, 2025

Washington D.C., October 10, 2025 – The financial markets are bracing for impact as the September 2025 Consumer Price Index (CPI) report looms, a critical piece of economic data that promises to shine...

Via MarketMinute

Topics Bonds Economy World Trade

UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments ↗

October 10, 2025

UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.

Via Benzinga

Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation

October 09, 2025

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Zoetis (NYSE:ZTS) Signals Robust Health with Q4 2025 Dividend Declaration, Bolstering Investor Confidence in Animal Health Sector

October 09, 2025

Parsippany, N.J. – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This...

Via MarketMinute

Topics Economy

Zoetis (NYSE:ZTS) Declares $0.50 Q4 2025 Dividend, Signaling Robust Animal Health Market

October 09, 2025

NEW YORK, NY – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today announced a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This...

Via MarketMinute

Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds

October 09, 2025

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...

Via MarketMinute

Topics Economy Intellectual Property Retirement

Behind the Scenes of Merck & Co's Latest Options Trends ↗

October 09, 2025

Via Benzinga

5 Healthcare Plays Powering the Sector’s Big Comeback ↗

October 09, 2025

After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.

Via MarketBeat

Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025

October 09, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025

October 09, 2025

From Merck Sharp & Dohme

Via Business Wire

MERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 08, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Merck, Doctors Reject Proposal To Break Up Combined MMR Vaccine ↗

October 07, 2025

Merck and health experts push back against U.S. officials' call to split the MMR vaccine, warning it could delay immunizations and weaken immune response.

Via Benzinga

How Arcus Biosciences Aims To Take On Merck In Cancer Treatment ↗

October 07, 2025

Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug.

Via Investor's Business Daily

Merck Completes Acquisition of Verona Pharma

October 07, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases

October 06, 2025

From Merck Sharp & Dohme

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.